Gilead rubbishes claim that antiviral drug, Remdesivir, failed to help Coronavirus patients in Chinese trial

Doctors suggest antiviral drugs would be most effective when administered as early as possible as it helps keep the virus from replicating in the blood.

Reuters April 24, 2020 09:15:29 IST
Gilead rubbishes claim that antiviral drug, Remdesivir, failed to help Coronavirus patients in Chinese trial

A closely-watched Gilead Sciences Inc experimental antiviral drug failed to help patients with severe COVID-19 in a clinical trial conducted in China, but the drugmaker said the findings were inconclusive because the study was terminated early.

Gilead shares closed down 4.3 percent after the data was inadvertently released and first reported by the Financial Times. It comes days after another report detailed rapid recovery in fever and respiratory symptoms in some patients with COVID-19 - the sometimes deadly respiratory illness caused by the coronavirus - who were treated with remdesivir at the University of Chicago Medicine hospital.

Gilead rubbishes claim that antiviral drug Remdesivir failed to help <span class=coronavirus patients in Chinese trial" width="1280" height="720" />

In the Chinese trial remdesivir was given by intravenous infusion

Interest in Gilead’s remdesivir has been high as there are currently no approved treatments or preventive vaccines for COVID-19 , and doctors are desperate for anything that might alter the course of the disease that attacks the lungs and can shut down other organs in extremely severe cases.

In the Chinese trial remdesivir, given by intravenous infusion, failed to improve patients’ condition or reduce the pathogen’s presence in the bloodstream, according to draft documents published accidentally by the World Health Organization (WHO).

But details were thin and suggested limitations in interpreting the data that has not yet been fully reviewed.

A screenshot of the WHO posting, captured by the medical news website STAT before it was taken down, said the trial enrolled 237 patients with 158 receiving remdesivir compared with 79 who got a placebo.

The rate of death was similar at 13.9 percent for remdesivir versus 12.8 percent in the control group.

“It’s still not that large of a study and therefore the statistics coming out of the trial aren’t exactly robust,” Mizuho analyst Salim Syed said in a research note.

Gilead in a statement said the WHO posting included inappropriate characterizations of the study, which was terminated early due to low enrollment and, as a result, cannot be used to make statistically meaningful conclusions.

“The study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in the disease,” the company said without providing details to back up that assertion.

Also read: coronavirus "}" data-sheets-userformat="{"2":513,"3":{"1":0},"12":0}">Newborn baby in London becomes the youngest person to be infected with coronavirus

Doctors have speculated that an antiviral drug like remdesivir would likely be most effective when administered as early as possible in the course of the disease as it is designed to help keep the virus from replicating in the blood.

“You can put out a campfire, but once it becomes a wildfire it’s hard to control,” said Dr Kevin Grimes, an infectious disease specialist at Houston Methodist Hospital who was not involved in the study.

The WHO said the draft manuscript is undergoing peer review before it will be officially released.

David Katz, chief investment officer at Matrix Asset Advisors, which owns Gilead shares, noted that multiple clinical studies remained ongoing for remdesivir and said, “we would not be selling (the stock) into weakness today.”

Gilead is awaiting results of a trial of remdesivir, which previously failed as an Ebola treatment, in 400 patients hospitalized with severe COVID-19 , with data expected later this month.

A separate trial in China testing the drug in patients with more moderate symptoms last week was also suspended due to a lack of eligible patients.

Brad Loncar, whose Loncar Investments runs a cancer immunotherapy ETF, was not ready to draw conclusions from the latest China data.

“Just as it was too much of a reach to be optimistic about positive anecdotes we have heard, I think it’s too pessimistic to write it off based on this (incomplete) data.”

Also Read: How COVID-19 testing kits work and new testing tech currently in development

Updated Date:

also read

COVID-19 updates: SC slams Centre's vaccination policy, seeks purchase data; India sees 1.32 lakh new cases
India

COVID-19 updates: SC slams Centre's vaccination policy, seeks purchase data; India sees 1.32 lakh new cases

Meanwhile,Odisha chief minister Naveen Patnaik wrote to all the chief ministers in the country, urging them to build a consensus over procurement of the COVID vaccines by the Centre for distribution among the states

Hyderabad-based Biological E to manufacture Canadian firm Providence's COVID 19 vaccine
India

Hyderabad-based Biological E to manufacture Canadian firm Providence's COVID 19 vaccine

Biological E will conduct a bridging trial for the vaccine in India and also manufacture the vaccine.

DGHS issues COVID-19 treatment guidelines: Here is what document recommends on Remdesivir, Tocilizumab
India

DGHS issues COVID-19 treatment guidelines: Here is what document recommends on Remdesivir, Tocilizumab

Among the drugs and treatment methods that have been removed from the recommendations are Ivermectin, Azithromycin and plasma therapy